# XTL Biopharmaceuticals Posts $0.00 GAAP EPS for First Half

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/60916
Published: 2026-11-18T22:46:56.000Z
Updated: 2026-11-18T22:46:56.000Z
Section: Business

> Cash and cash equivalents were approximately $1.80 million at June 30, 2026, up from approximately $0.08 million on Dec. 31, 2025.

XTL Biopharmaceuticals Ltd. posted first-half GAAP earnings per share of $0.00.

Cash and cash equivalents totaled approximately $1.80 million on June 30, 2026, compared with approximately $0.08 million on Dec. 31, 2025.


